Table 1.

Demographic and clinical characteristics of the 15 study patients with adult-onset Still’s disease treated with tocilizumab.

Characteristicn (%) or Mean ± SD
Men9 (60)
Age, yrs33 ± 12
Disease duration, yrs9 ± 11
Arthralgias15 (100)
Fever9 (60)
Rash7 (46)
Sore throat3 (20)
Pleuritis3 (20)
Mean prednisone dosage, mg/d27.6 ± 26.3
DMARD, n (mean)3.6 (range 1–7)
Previous treatment with ≥ 1 TNF-α blocker10 (66)
  • DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor.